% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Galldiks:874903,
author = {Galldiks, Norbert and Werner, Jan-Michael and Tscherpel,
Caroline and Fink, Gereon R and Langen, Karl-Josef},
title = {{I}maging findings following regorafenib in malignant
gliomas: {FET} {PET} adds valuable information to anatomical
{MRI}},
journal = {Neuro-oncology advances},
volume = {1},
number = {1},
issn = {2632-2498},
address = {Oxford},
publisher = {Oxford University Press},
reportid = {FZJ-2020-01691},
pages = {vdz038},
year = {2019},
abstract = {The prospective REGOMA phase 2 trial showed an encouraging
and significant median progression-free and overall survival
(PFS, OS) benefit for glioblastoma patients at first
progression treated with the oral multikinase inhibitor
regorafenib compared to lomustine monotherapy.1 In
particular, the OS benefit was 1.8 months compared to
lomustine (7.4 vs. 5.6 months; P = .0009), and the hazard
ratio was 0.5 $(95\%$ confidence interval, 0.33–0.75).
Interestingly, despite unchanged MRI findings at first
follow-up (“Stable Disease,” $39\%)$ following
regorafenib, complete or partial radiological responses
according to the RANO criteria2 were only seen in $5\%$ of
cases treated with regorafenib. On the other hand, $59\%$ of
patients in the regorafenib arm had grade 3–4 adverse
events.},
cin = {INM-3 / INM-4},
cid = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32642667},
UT = {WOS:000886002700031},
doi = {10.1093/noajnl/vdz038},
url = {https://juser.fz-juelich.de/record/874903},
}